Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://link.springer.com/article/10.1007/s12031-002-0026-2, but it redirected us to https://link.springer.com/article/10.1007/s12031-002-0026-2. The analysis below is for the second page.

Title[redir]:
Statin therapy for Alzheimer’s disease | Journal of Molecular Neuroscience
Description:
Disease-modifying therapies are being developed for Alzheimer’s disease (AD). These are expected to slow the clinical progression of the disease or delay its onset. Cerebral accumulation of amyloid β (Aβ) peptides is an early and perhaps necessary event for establishing AD pathology. Consequently therapies aimed at attenuating brain amyloidosis are expected to be disease modifying. Based on the epidemiological evidence pointing to a link between cholesterol metabolism and AD and the numerous laboratory studies implicating cholesterol in the process of Aβ production and accumulation, it is now believed that cholesterol-lowering therapies will be of value as disease modifying agents. Several epidemiological studies revealed that statin use for the treatment of coronary arterial disease is associated with a decreased prevalence or a decreased risk of developing AD. These observations require both preclinical and clinical validation. The former involves testing statins in one or more animal models of AD in order to establish which disease features are affected by statin treatment, the relative efficacy with which different statins modify these features and the mechanism(s) by which statins affect AD phenotypes. The latter requires prospective, randomized, placebo controlled trials to evaluate the effect of statin treatment on cognitive and AD biomarker outcomes. We have initiated a study aimed at determining the effects of atorvastatin (LipitorR), a statin with the largest US market share, on brain Aβ deposition in the PSAPP transgenic mouse model of Alzheimer’s amyloidosis. Our results indicate that Lipitor treatment markedly attenuates Aβ deposition in this animal model.

Matching Content Categories {📚}

  • Health & Fitness
  • Science
  • Education

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We're unsure if the website is profiting.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Doi.org might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

article, google, scholar, cas, pubmed, disease, alzheimers, cholesterol, amyloid, statins, statin, sci, therapy, betaamyloid, privacy, cookies, content, journal, research, pathology, treatment, risk, study, model, access, neurol, publish, search, petanceska, pappolla, refolo, clinical, effects, transgenic, dementia, precursor, protein, acad, usa, data, information, log, august, suzana, derosa, olm, therapies, brain, link, decreased,

Topics {✒️}

month download article/chapter putative disease-modifying therapy unique amyloid beta-protein beta-amyloid immunore-activity low-density lipoprotein-cholesterol tara thomas-bryant hmg-coa reductase inhibitors accelerated alzheimer-type phenotype amyloid precursor protein effective antiatherosclerotic therapy full article pdf cholesterol-lowering therapies privacy choices/manage cookies molecular neuroscience aims transgenic mouse model placebo controlled trials human beta-amyloid amyloid beta proteins cholesterol acyltransferase modulates epidemiological studies revealed epidemiological evidence pointing amyloid beta-peptide serum total cholesterol august 2002 volume 19 transgenic mice carrying disease modifying agents statin therapy animal model cholesterol depletion inhibits european economic area brain aβ deposition 3-hydroxy-3-methylglutaryl coenzyme 3-hydroxy3-methylglutaryl coenzyme total cholesterol level conditions privacy policy coronary arterial disease coronary artery disease dietary fat intake subjects taking statins case-control study ad biomarker outcomes accepting optional cookies preclinical development published related subjects age-related change article journal establishing ad pathology involves testing statins journal finder publish cholesterol-dependent generation

Questions {❓}

  • (1997) Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer’s disease?
  • Will it work?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Statin therapy for Alzheimer’s disease
         description:Disease-modifying therapies are being developed for Alzheimer’s disease (AD). These are expected to slow the clinical progression of the disease or delay its onset. Cerebral accumulation of amyloid β (Aβ) peptides is an early and perhaps necessary event for establishing AD pathology. Consequently therapies aimed at attenuating brain amyloidosis are expected to be disease modifying. Based on the epidemiological evidence pointing to a link between cholesterol metabolism and AD and the numerous laboratory studies implicating cholesterol in the process of Aβ production and accumulation, it is now believed that cholesterol-lowering therapies will be of value as disease modifying agents. Several epidemiological studies revealed that statin use for the treatment of coronary arterial disease is associated with a decreased prevalence or a decreased risk of developing AD. These observations require both preclinical and clinical validation. The former involves testing statins in one or more animal models of AD in order to establish which disease features are affected by statin treatment, the relative efficacy with which different statins modify these features and the mechanism(s) by which statins affect AD phenotypes. The latter requires prospective, randomized, placebo controlled trials to evaluate the effect of statin treatment on cognitive and AD biomarker outcomes. We have initiated a study aimed at determining the effects of atorvastatin (LipitorR), a statin with the largest US market share, on brain Aβ deposition in the PSAPP transgenic mouse model of Alzheimer’s amyloidosis. Our results indicate that Lipitor treatment markedly attenuates Aβ deposition in this animal model.
         datePublished:
         dateModified:
         pageStart:155
         pageEnd:161
         sameAs:https://doi.org/10.1007/s12031-002-0026-2
         keywords:
            Amyloid
            cholesterol
            statin
            therapy
            animal model
            Neurosciences
            Neurochemistry
            Cell Biology
            Proteomics
            Neurology
         image:
         isPartOf:
            name:Journal of Molecular Neuroscience
            issn:
               1559-1166
               0895-8696
            volumeNumber:19
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Humana Press
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Suzana S. Petanceska
               affiliation:
                     name:Nathan S. Kline Institute for Psychiatric Research
                     address:
                        name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Steven DeRosa
               affiliation:
                     name:Nathan S. Kline Institute for Psychiatric Research
                     address:
                        name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Vicki Olm
               affiliation:
                     name:Nathan S. Kline Institute for Psychiatric Research
                     address:
                        name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Nichole Diaz
               affiliation:
                     name:Nathan S. Kline Institute for Psychiatric Research
                     address:
                        name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ali Sharma
               affiliation:
                     name:Nathan S. Kline Institute for Psychiatric Research
                     address:
                        name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Tara Thomas-Bryant
               affiliation:
                     name:University of South Alabama Medical School
                     address:
                        name:Department of Pathology, University of South Alabama Medical School, Mobile
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Karen Duff
               affiliation:
                     name:Nathan S. Kline Institute for Psychiatric Research
                     address:
                        name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Miguel Pappolla
               affiliation:
                     name:University of South Alabama Medical School
                     address:
                        name:Department of Pathology, University of South Alabama Medical School, Mobile
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lorenzo M. Refolo
               affiliation:
                     name:Institute for the Study of Aging
                     address:
                        name:Institute for the Study of Aging, New York
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Statin therapy for Alzheimer’s disease
      description:Disease-modifying therapies are being developed for Alzheimer’s disease (AD). These are expected to slow the clinical progression of the disease or delay its onset. Cerebral accumulation of amyloid β (Aβ) peptides is an early and perhaps necessary event for establishing AD pathology. Consequently therapies aimed at attenuating brain amyloidosis are expected to be disease modifying. Based on the epidemiological evidence pointing to a link between cholesterol metabolism and AD and the numerous laboratory studies implicating cholesterol in the process of Aβ production and accumulation, it is now believed that cholesterol-lowering therapies will be of value as disease modifying agents. Several epidemiological studies revealed that statin use for the treatment of coronary arterial disease is associated with a decreased prevalence or a decreased risk of developing AD. These observations require both preclinical and clinical validation. The former involves testing statins in one or more animal models of AD in order to establish which disease features are affected by statin treatment, the relative efficacy with which different statins modify these features and the mechanism(s) by which statins affect AD phenotypes. The latter requires prospective, randomized, placebo controlled trials to evaluate the effect of statin treatment on cognitive and AD biomarker outcomes. We have initiated a study aimed at determining the effects of atorvastatin (LipitorR), a statin with the largest US market share, on brain Aβ deposition in the PSAPP transgenic mouse model of Alzheimer’s amyloidosis. Our results indicate that Lipitor treatment markedly attenuates Aβ deposition in this animal model.
      datePublished:
      dateModified:
      pageStart:155
      pageEnd:161
      sameAs:https://doi.org/10.1007/s12031-002-0026-2
      keywords:
         Amyloid
         cholesterol
         statin
         therapy
         animal model
         Neurosciences
         Neurochemistry
         Cell Biology
         Proteomics
         Neurology
      image:
      isPartOf:
         name:Journal of Molecular Neuroscience
         issn:
            1559-1166
            0895-8696
         volumeNumber:19
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Humana Press
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Suzana S. Petanceska
            affiliation:
                  name:Nathan S. Kline Institute for Psychiatric Research
                  address:
                     name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Steven DeRosa
            affiliation:
                  name:Nathan S. Kline Institute for Psychiatric Research
                  address:
                     name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Vicki Olm
            affiliation:
                  name:Nathan S. Kline Institute for Psychiatric Research
                  address:
                     name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Nichole Diaz
            affiliation:
                  name:Nathan S. Kline Institute for Psychiatric Research
                  address:
                     name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ali Sharma
            affiliation:
                  name:Nathan S. Kline Institute for Psychiatric Research
                  address:
                     name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Tara Thomas-Bryant
            affiliation:
                  name:University of South Alabama Medical School
                  address:
                     name:Department of Pathology, University of South Alabama Medical School, Mobile
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Karen Duff
            affiliation:
                  name:Nathan S. Kline Institute for Psychiatric Research
                  address:
                     name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Miguel Pappolla
            affiliation:
                  name:University of South Alabama Medical School
                  address:
                     name:Department of Pathology, University of South Alabama Medical School, Mobile
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lorenzo M. Refolo
            affiliation:
                  name:Institute for the Study of Aging
                  address:
                     name:Institute for the Study of Aging, New York
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Journal of Molecular Neuroscience
      issn:
         1559-1166
         0895-8696
      volumeNumber:19
Organization:
      name:Humana Press
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Nathan S. Kline Institute for Psychiatric Research
      address:
         name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
         type:PostalAddress
      name:Nathan S. Kline Institute for Psychiatric Research
      address:
         name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
         type:PostalAddress
      name:Nathan S. Kline Institute for Psychiatric Research
      address:
         name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
         type:PostalAddress
      name:Nathan S. Kline Institute for Psychiatric Research
      address:
         name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
         type:PostalAddress
      name:Nathan S. Kline Institute for Psychiatric Research
      address:
         name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
         type:PostalAddress
      name:University of South Alabama Medical School
      address:
         name:Department of Pathology, University of South Alabama Medical School, Mobile
         type:PostalAddress
      name:Nathan S. Kline Institute for Psychiatric Research
      address:
         name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
         type:PostalAddress
      name:University of South Alabama Medical School
      address:
         name:Department of Pathology, University of South Alabama Medical School, Mobile
         type:PostalAddress
      name:Institute for the Study of Aging
      address:
         name:Institute for the Study of Aging, New York
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Suzana S. Petanceska
      affiliation:
            name:Nathan S. Kline Institute for Psychiatric Research
            address:
               name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Steven DeRosa
      affiliation:
            name:Nathan S. Kline Institute for Psychiatric Research
            address:
               name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
               type:PostalAddress
            type:Organization
      name:Vicki Olm
      affiliation:
            name:Nathan S. Kline Institute for Psychiatric Research
            address:
               name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
               type:PostalAddress
            type:Organization
      name:Nichole Diaz
      affiliation:
            name:Nathan S. Kline Institute for Psychiatric Research
            address:
               name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
               type:PostalAddress
            type:Organization
      name:Ali Sharma
      affiliation:
            name:Nathan S. Kline Institute for Psychiatric Research
            address:
               name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
               type:PostalAddress
            type:Organization
      name:Tara Thomas-Bryant
      affiliation:
            name:University of South Alabama Medical School
            address:
               name:Department of Pathology, University of South Alabama Medical School, Mobile
               type:PostalAddress
            type:Organization
      name:Karen Duff
      affiliation:
            name:Nathan S. Kline Institute for Psychiatric Research
            address:
               name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
               type:PostalAddress
            type:Organization
      name:Miguel Pappolla
      affiliation:
            name:University of South Alabama Medical School
            address:
               name:Department of Pathology, University of South Alabama Medical School, Mobile
               type:PostalAddress
            type:Organization
      name:Lorenzo M. Refolo
      affiliation:
            name:Institute for the Study of Aging
            address:
               name:Institute for the Study of Aging, New York
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
      name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
      name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
      name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
      name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
      name:Department of Pathology, University of South Alabama Medical School, Mobile
      name:Dementia Research Group, Nathan S. Kline Institute for Psychiatric Research, Orangeburg
      name:Department of Pathology, University of South Alabama Medical School, Mobile
      name:Institute for the Study of Aging, New York
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(181)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Crossref

3.93s.